|
Daratumumab and Hyaluronidase-fihj Clinical Trials
5 actively recruiting trials across 3 locations
Also known as: DARA Co-formulated with rHuPH20, DARA/rHuPH20, DARZALEX FASPRO, Daratumumab, Daratumumab + rHuPH20 +8 more
Pipeline
Phase 2: 2Phase 3: 3
Top Sponsors
- SWOG Cancer Research Network2
- Suzanne Lentzsch, MD1
- NYU Langone Health1
- ECOG-ACRIN Cancer Research Group1
Indications
- Cancer5
- Plasma Cell Myeloma2
- Amyloid Light-chain Amyloidosis1
- Non-small Cell Lung Cancer With STK11/LKB1 Mutation1
- AL Amyloidosis1
Anchorage, Alaska2 trials
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Anchorage Associates in Radiation Medicine
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Anchorage Associates in Radiation Medicine
Phase 3
New York, New York2 trials
Daratumumab in STK11 Mutated NSCLC
NYU Langone Health
Phase 2
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University Irving Medical Center
Phase 2
Derby, Connecticut1 trial
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Smilow Cancer Hospital-Derby Care Center
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.